| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
INVITED REVIEW AND COMMENTARY |
From the Department of Surgery, Division of Thoracic Surgery (Dr V. Donnenberg), and the Department of Medicine, Division of Hematology Oncology (Dr A. Donnenberg), University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pennsylvania.
The failure to eradicate cancer may be as fundamental as a misidentification of the target. Current therapies succeed at eliminating bulky disease but often miss a tumor reservoir that is the source of disease recurrence and metastasis. Recent advances in the understanding of tissue development and repair cause us to revisit the process of drug resistance as it applies to oncogenesis and tumor heterogeneity. The cancer stem cell hypothesis states that the cancer-initiating cell is a transformed tissue stem cell, which retains the essential property of self-protection through the activity of multiple drug resistance (MDR) transporters. This resting constitutively drug-resistant cell remains at low frequency among a heterogeneous tumor mass. In the context of this hypothesis, the authors review the discovery of MDR transporters in cancer and normal stem cells and the failure of MDR reversal agents to increase the therapeutic index of substrate antineoplastic agents.
Key Words: Cancer stem cell • multiple drug resistance • chemotherapy • oncogenesis
Address for reprints: Vera S. Donnenberg, PhD, Hillman Cancer Research Center, 5117 Centre Avenue, Suite 2.42, Pittsburgh, PA 15213.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Short and D. T. Curiel Oncolytic adenoviruses targeted to cancer stem cells Mol. Cancer Ther., August 1, 2009; 8(8): 2096 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Abraham, M. Edgerly, R. Wilson, C. Chen, A. Rutt, S. Bakke, R. Robey, A. Dwyer, B. Goldspiel, F. Balis, et al. A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine Clin. Cancer Res., May 15, 2009; 15(10): 3574 - 3582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Tancred, A. R. Belch, T. Reiman, L. M. Pilarski, and J. Kirshner Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance J. Histochem. Cytochem., March 1, 2009; 57(3): 239 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Miele, N. Takebe, and S. P. Ivy The Cancer Stem Cell Hypothesis, Embryonic Signaling Pathways, and Therapeutics: Targeting an Elusive Concept ASCO Educational Book, January 1, 2009; 2009(1): 145 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-l. Dai, A. K. Tiwari, C.-P. Wu, X.-d. Su, S.-R. Wang, D.-g. Liu, C. R. Ashby Jr., Y. Huang, R. W. Robey, Y.-j. Liang, et al. Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2 Cancer Res., October 1, 2008; 68(19): 7905 - 7914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Riedel, A. Porrello, E. Pontzer, E. J. Chenette, D. S. Hsu, B. Balakumaran, A. Potti, J. Nevins, and P. G. Febbo A genomic approach to identify molecular pathways associated with chemotherapy resistance Mol. Cancer Ther., October 1, 2008; 7(10): 3141 - 3149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kirshner, K. J. Thulien, L. D. Martin, C. Debes Marun, T. Reiman, A. R. Belch, and L. M. Pilarski A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma Blood, October 1, 2008; 112(7): 2935 - 2945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Kaye Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here? J. Clin. Oncol., June 1, 2008; 26(16): 2616 - 2618. [Full Text] [PDF]
|
|
|
|
|
|
J. Fan, J. Stanfield, Y. Guo, J. A. Karam, E. Frenkel, X. Sun, and J.-T. Hsieh Effect of Trans-2,3-Dimethoxycinnamoyl Azide on Enhancing Antitumor Activity of Romidepsin on Human Bladder Cancer Clin. Cancer Res., February 15, 2008; 14(4): 1200 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. d'Amato, R. J. Landreneau, W. Ricketts, W. Huang, R. Parker, E. Mechetner, I.-R. Yu, and J. D. Luketich Chemotherapy resistance and oncogene expression in non-small cell lung cancer J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 352 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Surowiak, V. Materna, I. Kaplenko, M. Spaczynski, B. Dolinska-Krajewska, E. Gebarowska, M. Dietel, M. Zabel, and H. Lage ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome Clin. Cancer Res., December 1, 2006; 12(23): 7149 - 7158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Selbo, A. Weyergang, A. Bonsted, S. G. Bown, and K. Berg Photochemical Internalization of Therapeutic Macromolecular Agents: A Novel Strategy to Kill Multidrug-Resistant Cancer Cells J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 604 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Jordan, M. L. Guzman, and M. Noble Cancer stem cells. N. Engl. J. Med., September 21, 2006; 355(12): 1253 - 1261. [Full Text] [PDF]
|
|
|
|
|
|
X. Fan, W. Matsui, L. Khaki, D. Stearns, J. Chun, Y.-M. Li, and C. G. Eberhart Notch Pathway Inhibition Depletes Stem-like Cells and Blocks Engraftment in Embryonal Brain Tumors. Cancer Res., August 1, 2006; 66(15): 7445 - 7452. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
